Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric pulses plus chemo aimed at rare tumor, but study pulled

NCT ID NCT06660121

Disease control Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test electrochemotherapy (ECT) with bleomycin in people with desmoid fibromatosis, a non-cancerous but locally aggressive tumor. The goal was to see if the treatment could shrink the tumor and improve symptoms like pain. However, the study was withdrawn before any patients were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bleomycin
What this could lead to
If successful, this approach could offer a new localized treatment option for desmoid fibromatosis when surgery or other therapies are not possible.
What could go wrong
The study was withdrawn before enrolling any participants, so no results are available. The treatment involves chemotherapy and electrical pulses, which carry risks like pain, infection, or tissue damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Oct 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with diagnosis of desmoid fibromatosis with an indication for electrochemotherapy treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic Desmoid Fibromatosis and in active phase (documented growth at last follow-up) * Patients not eligible for surgery, cryoablation, or embolization * Signature of study-specific informed consent. Exclusion Criteria: * Patients with fibromatosis not in active phase, documented clinically and with imaging investigations (MRI, CT) * Patients with documented active infection * Previous treatment for \< 30 days * Pregnancy and lactation status * Patients of childbearing age without contraceptive use for at least 3 months * Presence of metal synthetic media at the site of treatment * COPD with FiO2 \< 30 mmHg * Impaired renal function with eGFR

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Desmoid fibromatosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

desmoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Desmoid fibromatosis

Contacts and locations

Locations

  • IRCCS Istituto Ortopedico Rizzoli

    Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.